AIDS Weekly & Law
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly & Law
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GlaxoSmithKline
Head-to-Head 96-Week Study Shows EPZICOM is Comparable to Truvada in Efficacy and Safety Measures in HIV Treatment-Naive Patients
August 21st, 2008
GlaxoSmithKline (NYSE:GSK) announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) (tenofovir DF + emtricitabine) as a first-line option for the treatment of HIV. The data were presented today at the 17th International AIDS Conference in Mexico City, Mexico. HEAT is the first large, prospective, long-term, head-to-head trial to evaluate the safety and efficacy of EPZICOM and Truvada both combined with a boosted protease inhibitor (Kaletra) administered once-daily in adults who had no previous exposure to HIV medicines. The study involved 688 HIV therapy-naive patients: 343...
Source: AIDS Weekly & Law (2008-08-21)
|
